title: Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
abstract: Twenty-one patients with previously untreated acute leukemia were treated with a combination chemotherapy of 120-200 mg/m2 of aclacinomycin A (ACM-A) in five divided daily doses and behenoyl-arabinofuranosylcytosine (BH-AC) 200-250 mg/m2 for 7 days at Saitama Cancer Center between April 1980 and July 1983. Complete remission was obtained in 12 of 21 patients (57.1%; M1 0/1, M2 10/10, M3 0/2, M4 1/3, leukemic transformation from sideroblastic anemia 0/1, refractory anemia with excess of blasts in transformation 1/2, chronic myelomonocytic leukemia 0/1). Seven of 9 patients who failed to have complete remission were crossed over to a combination chemotherapy of daunorubicin (DNR) plus BH-AC or cytosine arabinoside (ara-C), or single DNR for patients with M3, yielding complete remission in 5 patients. Seven patients received a total cumulative dose of more than 600 mg/m2 of ACM-A. The maximum dose given was 2,000 mg/m2. No congestive heart failure has yet been experienced. The median survival time was 12 months. These results have demonstrated that a combination of ACM-A and BH-AC shows almost equivalent activity with that of a standard induction therapy consisting of DNR plus ara-C. In addition, it was suggested that ACM-A plus BH-AC could be incorporated into reinforcement therapy because of supposedly less cardiac toxicity.
authors.forename: K
authors.initials: K
authors.lastname: Sampi
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneko
authors.forename: M
authors.initials: M
authors.lastname: Hattori
mesh_terms: D015250:Aclarubicin; D000206:Actuarial Analysis; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; C015019:enocitabine